Meeting
2012 ASCO Annual Meeting
Genetic variants associated with toxicity-related discontinuation of adjuvant aromatase inhibitor (AI) therapy.
Authors
Norah Lynn Henry
University of Michigan Medical Center, Ann Arbor, MI
Norah Lynn Henry , Todd C. Skaar , Jessica Dantzer , Lang Li , Anne T Nguyen , James M. Rae , Zeruesenay Desta , Steffi Oesterreich , Santosh Philips , Janet S Carpenter , Anna Maria Storniolo , Vered Stearns , Daniel F. Hayes , David A. Flockhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00228956
Citation
J Clin Oncol 30, 2012 (suppl; abstr 525)
DOI
10.1200/jco.2012.30.15_suppl.525
Abstract #
525
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS).
First Author: Fionnuala Crowley
Poster
2018 ASCO Annual Meeting
Association of a low-expression SLCO1B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer.
First Author: Jacqueline M Dempsey
First Author: Weimin Li
Poster
2012 Breast Cancer Symposium
Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting.
First Author: Susan Dent